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Abstract
Angioimmunoblastic T-cell lymphoma
(AITL) is a rare type of peripheral T-cell
lymphoma. Epstein-Barr virus (EBV) is
known to be associated with pathogenesis
and histological progression of AITL and
the onset of the disease often mimics an
infectious process. Here we describe two
cases of patients with serology for acute
EBV infection at the onset of AITL.
Introduction
Angioimmunoblastic T-cell lymphoma
(AITL) is a rare type of peripheral T-cell
lymphoma (PTCL) which accounts for 1-
2% of non Hodgkin lymphomas and has an
incidence of 0.05 new patient cases per
100,000 people in the USA, without sex
predilection. The median age of onset is 64
years and is associated with a very poor
prognosis.1,2 Clinically the disease presents
with systemic symptoms, prominent lym-
phadenopathy, hepatosplenomegaly, skin
involvement, polyclonal hypergammaglob-
ulinemia and autoimmune hemolytic ane-
mia.3,4 Lymph node histology shows an
effaced architecture, infiltration by T neo-
plastic cells (CD2+/CD3+/CD4+/CD10+/
CXCL13/PD1+), proliferation of high
endothelial venules and expanded follicular
dendritic cells (FDCs), in particular the
expansion of this type of cell is explained
by the recent identification of follicular
helper T cell (TFH) as the origin cell of the
tumor.5 Epstein-Barr virus (EBV) and
Human Herpes Virus 6 (HHV6) are known
to be associated with pathogenesis and his-
tological progression of AITL and the onset
of the disease often mimics an infectious
process.6 Here we describe two concomi-
tant cases of patients with serology for
acute EBV infection at the onset of AITL.
Case Report #1
In March 2016, a 34 years-old male
complaining fatigue and night sweats per-
sisting since one month together with
enlargement of a median submandibular
lymph node was examined by his primary
care physician. After an acute mononucleo-
sis infection was excluded by monospot
test, the patient was referred to our observa-
tion due to the worsening of clinical condi-
tions.
Enlarged lymph nodes in all the surface
anatomy stations and splenomegaly were
detectable by physical examination. Initial
laboratory tests showed mild anemia (Hb
10.7 g/dL), severe thrombocytopenia
(22,000/mmc), normal blood count
(8800/mmc) and differential, hyperuricemia
(8.5 mg/dL), increased lactate dehydroge-
nase (1138 U/L, normal range 240-480
U/L) and polyclonal hypergammaglobu-
linemia. Suspecting a lymphoproliferative
disease, excisional biopsy of an enlarged
right inguinal lymph node was performed.
Histological examination showed the pres-
ence of a diffuse infiltrate of T-cells (CD3+)
positive for CD4/PD1 and partially positive
for bcl6/CD10; a prominent vascular prolif-
eration, follicular dendritic cells expansion
were also described and clonal rearrange-
ments in T-cell receptor genes were detect-
ed. According to this finding, a diagnosis of
AITL was performed. The presence of rare
non-clonal B cells positive for EBV encod-
ed small RNA (EBER) was also reported
(Figure 1B). 
Bone marrow lymphoid infiltration was
detected on trephine biopsy and FDG-
PET/CT showed extensive involvement of
spleen and lymph nodes over and under the
diaphragm (Figure 2). A stage IVB disease
was assessed and the patient resulted at high
risk disease according to the new prognostic
index for AITL (PIAI index 3) with a
prospected 5-year overall survival probabil-
ity lower than 20%1.
Unexpectedly, microbiologic serologi-
cal screening revealed a positive antibody
panel for ongoing EBV infection due to the
detection of IgM antibodies to viral capsid
antigen (VCA), jointly to IgG antibodies to
VCA and EBV nuclear antigen (EBNA).
The EBV viral load in peripheral blood was
of 27,077 copies/mL. These findings, in
addition to the intense FDG-PET/CT tonsil-
lar glucose uptake, lead to consider a con-
comitant acute EBV infection.7,8
Interestingly the patient was a regular blood
donor; he was screened for EBV infection
few months before the diagnosis and his
antibody framework was compatible with
previous infection. The peripheral blood
smear showed a panel of morphologically
different cells, some compatible with lym-
phoid blast cells at immunophenotypic
analysis, (CD3-/CD4+/ CD10+/CD5+/
cyCD3+-) and others with Turk cells
(Figure 1A). A monospot test and an
immunophenotypic analysis from peripher-
al blood for infectious mononucleosis were
repeated, both with negative results.
The patient was hospitalized and treated
with a course of chemotherapy regimen
containing prednisone, etopside, vin-
cristine, cyclophosphamide and anthracy-
clines (DA-EPOCH) (without the
immunotherapy (Rituximab) because there
were no clonal B cell associated with
EBV).10
He was discharged home with excellent
response in adenopathy and in EBV viral
load (754 copies/mL) but within 5 days a
new enlargement of the tumor masses,
recurrence of leukemic cells in peripheral
blood (8%) and an increase in EBV viral
load (2829 copies/mL) were detected. As a
consequence, we decided to treat the patient
with a more intensive chemotherapy regi-
men containing cyclophosphamide with
high-doses of arabinosylcytosine and
methotrexate (HyperCHiDAM).11
After two cycles of chemotherapy the
patient obtained a radiological complete
remission of the disease, negativity of the
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viral load; the serology for EBV was com-
patible with a previous infection (VCA-
IgG+, EBNA-IgG+, VCA-IgM-). Actually,
4 months after the end of the treatment the
patient still maintain a complete remission
of disease and an allogenic stem cell trans-
plant is planned.
Case Report #2
Approximately two weeks later, a 61
years-old man was referred to our depart-
ment from a community hospital with a sus-
pected diagnosis of lymphoproliferative
disease. A few days before he went to the
emergency room for fatigue and exertional
dyspnea; on physical examination he had
enlarged lymph nodes in all the surface
anatomy stations and splenomegaly. Initial
laboratory tests revealed anemia (Hb 11
g/L), thrombocytopenia (38,000/mmc) and
increased white blood cells count
(27,230/mmc), increased lactate dehydroge-
nase (731 U/L). The immunoelectrophore-
sis revealed the presence of a small mono-
clonal IgG lambda component in absence of
hypergammaglobulinemia. During the hos-
pitalization he developed a worsening dysp-
nea associated with rapid onset of a massive
pleural effusion. A thoracentesis was per-
formed and the immunophenotypic assay of
the cells of pleural fluid sample was com-
patible with a T-cell lymphoproliferative
disease (CD4+, CD10+, CD5+, CyCD3+).
Peripheral blood examination was charac-
terized by the presence of 15% of immature
lymphoid cells. An axillary lymph node
biopsy and a bone marrow biopsy were
quickly performed. Unfortunately, his clini-
cal condition worsened rapidly and the
expired for an critical cardiac complication.
A few days after the patient death, the
lymph node histology revealed complete
effacement of nodal architecture, a diffuse
infiltrate of CD4+, PD1+ and CD10+ T-
cells associated with a monoclonal B-cell
population CD20+, MUM1+, CD30+/- and
EBV encoded small RNA +(EBER) (Figure
1C); again the diagnosis was angioim-
munoblastic T-cell lymphoma, confirmed
by bone marrow localization on trephine
biopsy. Unexpectedly the standard serology
tests revealed that EBV testing was positive
for IgG antibodies to viral capsid antigen
(VCA-IgG), EBV nuclear antigen (EBNA-
IgG) andIgM antibodies to viral capsid anti-
gen (VCA-IgM); it was too late for dosing
EBV-DNA in the blood-stream.
Discussion and Conclusions
A relationship between AITL and viral
infections, particularly EBV infection, is
suggested and the infection might con-
tribute to disease progression both from the
histological and clinical point of view.6 A
paper of Delfau-Larue described a strong
relationship between the presence of circu-
lating AITL tumor cells and higher levels of
peripheral EBV DNA at initial presentation
of disease. In addition, a high viremia at
onset would be associated with a poor
response to therapy.12 The cases described
confirm all of these relations. In fact the
change of clinical course towards greater
aggressiveness coincided with the detection
IgM anti VCA. Only one other case with an
acute serological profile for EBV infection
coexisting with angioimmunoblastic T-cell
lymphoma is reported in medical literature
by Beer. 9 The case described is very similar
to our first and in both patients a polyclonal
hypergammaglobulinemia was detected. It
may not be excluded that in this panel of
antibodies some recognized EBV with a
random cross reactivity. Also in the second
case we described IgM anti VCA that were
assessed in spite the patient did not present
hypergammaglobulinemia; unfortunately
we don’t have neither a data regarding
viremia nor a serology preceding disease
onset.
In our opinion, the important thing is
the temporary positive reaction of anti
VCA-IgM antibody in spite of the past
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Figure 1. A) Peripheral blood smear of the first patient. It shows a panel of morphologi-
cally different cells, some compatible with lymphoid blast cells and others with Turk cells.
B) Lymph node histology and EBER reaction of the first patient. Note the presence of
rare non-clonal B cells positive for EBV encoded small RNA (EBER). C) Lymph node his-
tology and EBER reaction of the first patient. In this case there is a monoclonal B-cell
population CD20+, MUM1+, CD30+/- and EBV encoded small RNA+ (EBER).











infection of EBV. This finding suggests the
following two mechanisms: a part of hyper-
gammaglobulinemia or reactivation of the
virus.
The relationship between EBV and
AITL is debated; some authors argue that
the presence of EBV reflects a profound
immunodeficiency due to AITL while oth-
ers argue that the EBV drives the develop-
ment or a rapid progression of the tumor.6
Also in our patients an EBV reactivation, or
maybe a de novo infection for the second
one, may have triggered a rapid progression
of disease. On the other hand, there are var-
ious evidences that in patients with AITL
continuous antigenic stimulation by EBV
may promote firstly the proliferation of
polyclonal B-lymphocytes in the neoplastic
microenvironment and successively the
appearance of genetic lesions driving the
development of a B-cell lymphoma. The
diagnosis of associated B-cell lymphoma
may be simultaneous to the diagnosis of
AITL: in this case the diagnosis is directly
the one of composite lymphoma.
Otherwise, the onset of B-cell lymphoma
may occur later.13-15
The cases we described stand as a con-
tribution in favor of EBV possible role in
the development or increased aggressive-
ness of AITL. Monitoring of EBV serology
to AITL diagnosis and during treatment
would be considered to add more data to
development research.
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